Healthy participant
Conditions
Interventions
Ingestion of the test food for 12 weeks
Ingestion of the placebo food for 12 weeks
Sponsors
Morinaga & Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Healthy male or female participants aged 40 to 69 years at the time of informed consent 2) Participants who can give informed consent to participate in this trial after being provided with an explanation of the protocol detail
Exclusion criteria
Exclusion criteria: Participants 1) who are currently receiving medication for any illness 2) who have or are being treated for dementia or other memory impairment disorders 3) who have routinely taken medication for disease treatment within the past month (excluding as-needed use for headache, menstrual pain, cold, etc.) 4) with a past or current history of serious disorders of the liver, kidney, heart, lung, blood, etc. 5) with concurrent or past gastrointestinal diseases (except for past diseases judged by the principal investigator not to affect participation in the study) 6) with food allergies (including a history of these allergies, especially milk and soy) 7) who are pregnant, lactating, or planning to become a pregnant during the study period 8) with alcoholism or other psychiatric disorders 9) who currently smoke 10) who may change their daily lifestyle habits during the study period (e.g., moving, night shift work, long trips, etc.) 11) who may develop seasonal allergic symptoms (e.g., hay fever) during the study period 12) who have a habit of continuously consuming foods with health claims (e.g., Foods for Specified Health Uses, and Foods with Function Claims), health foods, or supplements that claim to have effects on cognitive function, currently or within the past three months, or those who plan to take them during the study period 13) who currently or within the past three months have routinely taken drugs labeled or claimed to have effects on cognitive function 14) who have received inpatient medical treatment within the past six months, or who are expected to be hospitalized during the study period 15) who participated in another clinical study within the past one month, or who plan to participate in another clinical study during the study period 16) judged by the principal investigator to be unsuitable for study participation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitrax | — |
Countries
Japan
Contacts
Public ContactSadao Mori
Morinaga & Co., Ltd. R&D institute
Outcome results
None listed